Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference

November 25, 2014 – 11:00 am | Edit Post

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.

On December 2 at 11:40am Eastern Time (8:40am Pacific Time) he will make a presentation at the 2014 Deutsche Bank BioFEST in Boston. 

On December 3 at 12:00pm Eastern Time (9:00am Pacific Time) he will make a presentation at the 26th Annual Piper Jaffray Healthcare Conference in New York City.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.

Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference

November 25, 2014 – 11:00 am | Edit Post

SAN DIEGO, Nov. 25, 2014 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.

On December 2 at 11:40am Eastern Time (8:40am Pacific Time) he will make a presentation at the 2014 Deutsche Bank BioFEST in Boston. 

On December 3 at 12:00pm Eastern Time (9:00am Pacific Time) he will make a presentation at the 26th Annual Piper Jaffray Healthcare Conference in New York City.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company’s website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.

goBalto Selected as a 2014 Red Herring Top 100 Global Company

November 25, 2014 – 10:39 am | Edit Post

SAN FRANCISCO, Nov. 25, 2014 /PRNewswire/ – goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, has been recognized as a winner of Red Herring’s Top 100 Global award. goBalto also received a Global Top 100 North America award in 2013, marking its emergence as a top player in the international technology landscape.

Red Herring’s Top 100 Global list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work. 

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across the globe to the Top 100 winners. We believe goBalto embodies the vision, drive and innovation that define a successful entrepreneurial venture. goBalto should be proud of its accomplishment.”

Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track records and standing of startups relative to their peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models from around the world.

“We’re deeply honored to be recognized once again by Red Herring as a game-changing and life-changing company, and for being the only clinical solution to receive the award” said Sujay Jadhav, goBalto CEO. “We have a growing roster of global customers who are reaping the benefits of our solutions, to make their clinical study startup process shorter, more transparent, and much more efficient. I’m proud that we’re using technology to literally ‘change the way we live and work’. Anyone with a loved one whose life has been prolonged or saved by a drug or medical device understands how important it is to shorten the clinical trials process. Red Herring’s acknowledgment of our work demonstrates to a wide audience that this is exactly what we’re successfully doing.”

The Red Herring 2014 Top 100 Global winners were announced at the Red Herring Global 2014 forum in Los Angeles on November 18-20, 2014.

About goBalto

goBalto develops next-generation solutions that simplify and accelerate clinical study startup in the pharmaceutical, biotechnology, and medical device industries. Our management team has over 100 years of combined experience in the life sciences industry and enterprise software implementation. Our team has worked for such companies as Amgen, Genentech, Quintiles, Roche, Johnson & Johnson, and Model N. With a proven commitment to customer success, disruption, and study startup optimization, we’re changing the way our leading global pharma and CRO customers approach their business processes. Based in San Francisco, California, we have satellite offices in Pennsylvania and Singapore. For more information, visit www.gobalto.com.

Press contacts:Maria Breaux415.671.4372mbreaux@gobalto.com

Amanda JonesConnect Marketing801-373-7888amandaj@connectmarketing.com

Logo – http://photos.prnewswire.com/prnh/20141118/159334LOGO

SOURCE goBalto, Inc.

goBalto Selected as a 2014 Red Herring Top 100 Global Company

November 25, 2014 – 10:39 am | Edit Post

SAN FRANCISCO, Nov. 25, 2014 /PRNewswire/ – goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, has been recognized as a winner of Red Herring’s Top 100 Global award. goBalto also received a Global Top 100 North America award in 2013, marking its emergence as a top player in the international technology landscape.

Red Herring’s Top 100 Global list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work. 

“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across the globe to the Top 100 winners. We believe goBalto embodies the vision, drive and innovation that define a successful entrepreneurial venture. goBalto should be proud of its accomplishment.”

Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track records and standing of startups relative to their peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models from around the world.

“We’re deeply honored to be recognized once again by Red Herring as a game-changing and life-changing company, and for being the only clinical solution to receive the award” said Sujay Jadhav, goBalto CEO. “We have a growing roster of global customers who are reaping the benefits of our solutions, to make their clinical study startup process shorter, more transparent, and much more efficient. I’m proud that we’re using technology to literally ‘change the way we live and work’. Anyone with a loved one whose life has been prolonged or saved by a drug or medical device understands how important it is to shorten the clinical trials process. Red Herring’s acknowledgment of our work demonstrates to a wide audience that this is exactly what we’re successfully doing.”

The Red Herring 2014 Top 100 Global winners were announced at the Red Herring Global 2014 forum in Los Angeles on November 18-20, 2014.

About goBalto

goBalto develops next-generation solutions that simplify and accelerate clinical study startup in the pharmaceutical, biotechnology, and medical device industries. Our management team has over 100 years of combined experience in the life sciences industry and enterprise software implementation. Our team has worked for such companies as Amgen, Genentech, Quintiles, Roche, Johnson & Johnson, and Model N. With a proven commitment to customer success, disruption, and study startup optimization, we’re changing the way our leading global pharma and CRO customers approach their business processes. Based in San Francisco, California, we have satellite offices in Pennsylvania and Singapore. For more information, visit www.gobalto.com.

Press contacts:Maria Breaux415.671.4372mbreaux@gobalto.com

Amanda JonesConnect Marketing801-373-7888amandaj@connectmarketing.com

Logo – http://photos.prnewswire.com/prnh/20141118/159334LOGO

SOURCE goBalto, Inc.

Vegetable Oil Ingredient Key to Destroying Gastric Disease Bacteria

November 25, 2014 – 10:03 am | Edit Post

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

Vegetable Oil Ingredient Key to Destroying Gastric Disease Bacteria

November 25, 2014 – 10:03 am | Edit Post

The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils.

Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – November 25, 2014) – Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property…

Ignyta To Present At Upcoming Investor Conferences

November 24, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014: •The Piper Jaffray 26th Annual Healthcare Conference at the Palace Hotel in New York, NY on December 2, 2014 at 9:30 a.m. Eastern time (presentation by Jonathan…

Alphatec Spine To Present At Upcoming Investor Events In December 2014

November 24, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that the Company’s executives, Jim Corbett, President and Chief Executive Officer, and Mike O’Neill…

Alphatec Spine Announces Appointment Of To Its Board Of Directors

November 24, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Nov. 24, 2014 (GLOBE NEWSWIRE) — Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that its board of directors has appointed Tom C. Davis as a member of the board of directors, effectively…